Patents by Inventor Christophe Lacomme

Christophe Lacomme has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100173407
    Abstract: There is provided a method of inhibiting gene expression by locating a 5?-5 donor splicing site sequence in the 3? UTR of a gene or within coding sequence containing the stop codon of a gene. Stability of homologous mRNA in trans is also adversely affected leading to a reduction in expression. A polynucleotide containing a 5?-donor splicing site sequence in either coding sequence containing the stop codon or the 3? UTR is also provided and in one embodiment is in the form of a vector. The 5?-donor splicing site sequence can be present in multiple copies, for example as a tandem repeat. In one embodiment the 5-donor splicing site sequence has the sequence 5?-MAGGTRAGTA-3? where M is A or C and R is A or G.
    Type: Application
    Filed: January 30, 2008
    Publication date: July 8, 2010
    Applicant: SCOTTISH CROP RESEARCH INSTITUTE
    Inventors: Krzysztof Wypijewski, Christophe Lacomme, Gyorgy Hutvagner, Csaba Hornyik, Jane Shaw, Jennifer Stephens
  • Publication number: 20090055963
    Abstract: A novel VIGS vector is described based on pGR106. The vector includes a nucleotide silencing sequence which is homologous or complementary to a target gene of a host cell. The vector can induce gene silencing in whole plants and microplants and is also effective in the tubers of Solanum spp.
    Type: Application
    Filed: April 12, 2005
    Publication date: February 26, 2009
    Applicant: SCOTTISH CROP RESEARCH INSTITUTE
    Inventors: Christophe Lacomme, Mark Andrew Taylor, Paul Birch
  • Publication number: 20040053225
    Abstract: Virus-based expression vectors carrying sequences corresponding to endogenous host genes trigger silencing through a homology-dependent RNA degradation mechanism. Virus-induced gene silencing (VIGS), is useful as a reverse-genetic tool for use in functional genomic programs for loss-of-function transient assays-based screening. Described herein is an approach to enhance the robustness of the VIGS phenotype by increasing the level of dsRNA molecule production.
    Type: Application
    Filed: September 12, 2003
    Publication date: March 18, 2004
    Applicant: LARGE SCALE BIOLOGY CORPORATION
    Inventors: Gregory P. Pogue, Christophe Lacomme